JP5781941B2 - ステムドメインにおける欠失および挿入された異種配列を有する黄色ブドウ球菌の組換えα溶血素ポリペプチド - Google Patents

ステムドメインにおける欠失および挿入された異種配列を有する黄色ブドウ球菌の組換えα溶血素ポリペプチド Download PDF

Info

Publication number
JP5781941B2
JP5781941B2 JP2011545744A JP2011545744A JP5781941B2 JP 5781941 B2 JP5781941 B2 JP 5781941B2 JP 2011545744 A JP2011545744 A JP 2011545744A JP 2011545744 A JP2011545744 A JP 2011545744A JP 5781941 B2 JP5781941 B2 JP 5781941B2
Authority
JP
Japan
Prior art keywords
sequence
protein
recombinant
amino acid
icha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011545744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504301A5 (enExample
JP2013504301A (ja
Inventor
パトリス フィレーエ
パトリス フィレーエ
ヌーレディーヌ ラジー
ヌーレディーヌ ラジー
モレノ ガレーニ
モレノ ガレーニ
ベルナール タミニオー
ベルナール タミニオー
オリヴィエール ジョルワ
オリヴィエール ジョルワ
アルフレッド コーラル
アルフレッド コーラル
アラン ジャック
アラン ジャック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Brussel
Université Libre de Bruxelles
Original Assignee
Vrije Universiteit Brussel
Université Libre de Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Brussel, Université Libre de Bruxelles filed Critical Vrije Universiteit Brussel
Publication of JP2013504301A publication Critical patent/JP2013504301A/ja
Publication of JP2013504301A5 publication Critical patent/JP2013504301A5/ja
Application granted granted Critical
Publication of JP5781941B2 publication Critical patent/JP5781941B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011545744A 2009-01-19 2010-01-15 ステムドメインにおける欠失および挿入された異種配列を有する黄色ブドウ球菌の組換えα溶血素ポリペプチド Expired - Fee Related JP5781941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09150888.7 2009-01-19
EP09150888A EP2208787A1 (en) 2009-01-19 2009-01-19 A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
PCT/EP2010/050453 WO2010081875A1 (en) 2009-01-19 2010-01-15 A recombinant alpha-hemolysin polypeptide of staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted

Publications (3)

Publication Number Publication Date
JP2013504301A JP2013504301A (ja) 2013-02-07
JP2013504301A5 JP2013504301A5 (enExample) 2013-03-21
JP5781941B2 true JP5781941B2 (ja) 2015-09-24

Family

ID=40811673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545744A Expired - Fee Related JP5781941B2 (ja) 2009-01-19 2010-01-15 ステムドメインにおける欠失および挿入された異種配列を有する黄色ブドウ球菌の組換えα溶血素ポリペプチド

Country Status (7)

Country Link
US (1) US8545853B2 (enExample)
EP (2) EP2208787A1 (enExample)
JP (1) JP5781941B2 (enExample)
AU (1) AU2010205645B2 (enExample)
CA (1) CA2749862C (enExample)
ES (1) ES2483720T3 (enExample)
WO (1) WO2010081875A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
RS58190B2 (sr) * 2011-02-08 2021-08-31 Medimmune Llc Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
RU2632651C2 (ru) * 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
WO2012178093A1 (en) 2011-06-24 2012-12-27 Electronic Biosciences Inc. High contrast signal to noise ratio device components
CN102977214B (zh) * 2012-09-29 2014-03-12 重庆原伦生物科技有限公司 用于耐甲氧西林金黄色葡萄球菌（mrsa）疫苗的重组蛋白hf2及制备方法和应用
US10047129B2 (en) 2012-12-20 2018-08-14 Electronic Biosciences, Inc. Modified alpha hemolysin polypeptides and methods of use
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
MX377794B (es) * 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
KR101964619B1 (ko) * 2014-09-29 2019-04-02 후지필름 가부시키가이샤 항체 결합성 폴리펩타이드, 항체 결합성 융합 폴리펩타이드 및 흡착 재료
CN105641689B (zh) * 2016-01-21 2024-09-10 浙江海隆生物科技股份有限公司 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用
US11414464B2 (en) 2016-07-22 2022-08-16 Evaxion Biotech A/S Chimeric proteins for inducing immunity towards infection with S. aureus
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION AND USES THEREOF
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
CN113164580B (zh) 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗
MX2021004173A (es) 2018-10-09 2021-09-08 Medimmune Llc Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.
WO2024168197A2 (en) * 2023-02-08 2024-08-15 The Regents Of The University Of California Membrane translocation compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005167A1 (en) * 1997-07-25 1999-02-04 University Of Massachusetts Designed protein pores as components for biosensors
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
AU2001292674A1 (en) * 2000-09-15 2002-04-29 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CN1674933B (zh) * 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
JP2009539979A (ja) 2006-06-12 2009-11-19 ナビ バイオファーマシューティカルズ ブドウ球菌感染症を治療および予防するための、α毒素の使用

Also Published As

Publication number Publication date
EP2382316A1 (en) 2011-11-02
EP2208787A1 (en) 2010-07-21
EP2382316B1 (en) 2014-04-23
CA2749862C (en) 2015-02-24
US20120014983A1 (en) 2012-01-19
AU2010205645A1 (en) 2011-07-14
WO2010081875A1 (en) 2010-07-22
AU2010205645B2 (en) 2014-09-04
CA2749862A1 (en) 2010-07-22
US8545853B2 (en) 2013-10-01
ES2483720T3 (es) 2014-08-07
JP2013504301A (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
JP2013504301A (ja) ステムドメインにおける欠失および挿入された異種配列を有する黄色ブドウ球菌の組換えα溶血素ポリペプチド
CA2655133C (en) Use of alpha-toxin for treating and preventing staphylococcus infections
DK2668208T3 (en) The cross-reactive antibody Staphylococcus Aureus
CA2735171C (en) Prevention, treatment and diagnosis of p.gingivalis infection
KR20070058631A (ko) 면역원성 조성물
US20180179267A1 (en) Anti-staphylococcus aureus antibody combination preparation
AU2014270598B2 (en) Generation of highly potent antibodies neutralizing the LukGH (LukAB) toxin of Staphylococcus aureus
CN104768572B (zh) 葡萄球菌凝固酶抗原及其使用方法
Haghighat et al. Recombinant PBP2a as a vaccine candidate against methicillin-resistant Staphylococcus aureus: immunogenicity and protectivity
NZ565069A (en) Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
US20150165015A1 (en) Use of alpha-toxin for treating and preventing staphylococcus infections
US20230310543A1 (en) Novel composition for prevention or treatment of staphylococcus aureus infectious disease
HK40101755A (en) Novel composition for prevention or treatment of staphylococcus aureus infectious disease
WO2018093822A1 (en) Chimeric antibodies comprising binding domains of phage lysins, bacterial autolysins, bacteriocins, and phage tail or tail fibers
WO2008127102A1 (en) S. pnuemoniae transcytosis protein
HK1243089A1 (en) Immunogenic pcpa polypeptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140826

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150716

R150 Certificate of patent or registration of utility model

Ref document number: 5781941

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees